Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) signaling pathways (IL-6/TNF-α pathways)

The Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) signaling pathways represent a complex network of pro-inflammatory cascades essential for the human immune response. IL-6 is a pleiotropic cytokine that mediates the acute phase response and the transition from innate to adaptive immunity, primarily signaling through a hexameric receptor complex to activate the JAK/STAT3 pathway (UniProt P05231; PMC7147065). TNF-α is a potent pyrogen and inflammatory mediator that signals through TNFR1 and TNFR2 to activate NF-κB and MAPK pathways, regulating cell survival, proliferation, and programmed cell death (UniProt P01375; StatPearls NBK482457). Together, these pathways are frequently dysregulated in autoimmune and chronic inflammatory disorders, leading to persistent tissue damage and systemic inflammation (PubMed 28403641). Pharmacological targeting of these pathways, using biologics such as TNF inhibitors or IL-6 receptor antagonists, has revolutionized the treatment of diseases like rheumatoid arthritis and inflammatory bowel disease (Nature Reviews Drug Discovery nrd.2017.258). However, because these pathways are critical for host defense, their therapeutic inhibition carries significant risks of serious opportunistic infections, tuberculosis reactivation, and other immune-related adverse events (FDA Safety Information). Monitoring treatment efficacy often involves measuring downstream biomarkers such as C-reactive protein (CRP), which is strongly induced by the IL-6 pathway (PubMed 25590164).

Other names

IL-6/TNF axisPro-inflammatory cytokine signaling pathwaysIL6-TNF-alpha inflammatory cascadeCytokine-mediated signaling

Therapeutic agents target these pathways by neutralizing soluble and membrane-bound cytokines (TNF-α or IL-6) or by competitively inhibiting their respective receptors (TNFR or IL-6R) to prevent downstream signal transduction through NF-κB or JAK/STAT pathways.